Drug intelligence / Profile preview

AZR-GVD-009

Development stage: Preclinical
Lead developer: Azura Ophthalmics
Modality: Small Molecules
Administration: Ophthalmic

Overview

AZR-GVD-009 is a preclinical-stage therapeutic candidate being developed by Azura Ophthalmics for the treatment of Ocular Graft-versus-Host Disease (Ocular GvHD). Azura Ophthalmics specializes in topical ophthalmic formulations designed to treat lid-margin and meibomian gland-related pathologies. Ocular GvHD is a common and often severe complication of allogeneic hematopoietic stem cell transplantation, characterized by inflammation and damage to the ocular surface, including the meibomian glands. AZR-GVD-009 is intended to address the underlying ocular surface dysfunction in these patients, potentially utilizing the company's proprietary keratolytic platform to improve lid-margin health and tear film stability.

Beyond the preview

Go deeper on AZR-GVD-009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZR-GVD-009.

Explore the full profile